Regulatory/Legislative News

MILAN — In difficult eyes or eyes with comorbidities in which diffractive trifocal IOLs are not an option, the AcrySof IQ Vivity and Vivity toric extended depth of focus lenses are a useful alternative, according to one specialist here.

CHICAGO — California Gov. Gavin Newsom vetoed a bill that would have allowed optometrists in the state to use therapeutic lasers and perform other procedures.

This is a dry eye disease blog. From time immemorial, we have struggled with the out-of-pocket costs of the drugs we prescribe. All of those drugs enjoyed patent protection, allowing the manufacturers to control prices.

The Department of Justice and Federal Trade Commission announced that the government will collect $1.5 million in civil penalties and $2 million in consumer redress from the online contact lens company, Vision Path Inc., doing business as Hubble Contacts.

WAIKOLOA, Hawaii — Medicare payment changes, ASC payment rates and new FDA approved drugs were a few of the topics discussed in a presentation on 2022 updates for ophthalmic practices at Hawaiian Eye 2022.

Allergan, an AbbVie company, announced the FDA approval of the eye drop, Vuity, for the treatment of presbyopia.

Samsung Bioepis and Biogen’s collaboration on the approval of Byooviz, a biosimilar referencing Lucentis, ushers in a new period of biosimilar anti-VEGF biologics in retina and more choices for both patients and physicians.

WAILEA, Hawaii — “For those of you in retina or have retina in your practice I am sure this is a topic of conversation – the government is coming after anti-VEGF therapy from all directions,” said an expert in healthcare law.

Roclanda has received marketing authorization from the Medicines and Healthcare Products Regulatory Agency in Great Britain, according to a press release from Aerie Pharmaceuticals.

Wyoming has joined Mississippi in passing legislation to expand optometric scope of practice, including certain surgical and prescription rights.